ResearchAndMarkets.com has added the Cancer Vaccines Analytical Tool to its offering, providing continuously updated intelligence on cancer vaccine development, clinical trials, competitors, licensing, investment and commercial opportunities. During 2024 and 2025, the oncology pipeline recorded 76 new cancer vaccines, more than 300 drugs associated with key events and 1,946 events across 1,412 drug programs. The platform covers personalized neoantigen vaccines, armored vaccine technologies, mRNA platforms, combination immunotherapies, artificial intelligence, multi-omics and next-generation sequencing. It monitors more than 960 organizations and more than 2,100 drugs, including over 160 discovery-stage and 630 preclinical programs, alongside clinical, biomarker, deal, funding and investor data. Users receive one year of online access, monthly email alerts, exportable reports, training resources, 24/7 support and access through major browsers. The product is aimed at oncology developers, biotechnology and pharmaceutical companies, investors, academic institutions and business development teams.